非病毒递送碱基编辑器实现小鼠模型中B型血友病无义变异的个性化校正
本研究开发了基于脂质纳米颗粒(LNP)的非病毒碱基编辑策略,针对F9基因可被A•T到G•C碱基编辑校正的无义变异进行个性化治疗。在表达6种可校正变异的HEK293细胞中,SpRY-ABE8e碱基编辑器成功诱导所有靶位点的A>G转换。在B型血友病模型小鼠中,LNP递送碱基编辑器mRNA和guide RNA后恢复了致病变异(c.1068G>A为62.8%±14.4%,c.1222C>T为35.9%±3.8%,c.1292G>A为70.6%±2.7%)并提高了血浆FIX活性。
要点
- LNP递送SpRY-ABE8e碱基编辑器可校正F9基因多种无义变异
- 小鼠体内变异校正效率分别为62.8%、35.9%和70.6%
- 该策略可提高血浆FIX活性,代表潜在治愈性干预
核心结论
- 针对变异类型的非病毒碱基编辑平台可作为由单核苷酸变异导致的严重B型血友病的治愈性干预。
研究设计与样本
- 在携带F9变异的HEK293细胞中评估编辑效率,并在AAV8载体表达的B型血友病模型小鼠中评估体内功能与分子恢复。
- 通过静脉注射携带腺嘌呤碱基编辑器(Cas9切口酶偶联ABE8e)mRNA和相应guide RNA的脂质纳米颗粒。
主要发现
- 创建了稳定表达6种可校正无义变异的HEK293细胞:c.1067G>A、c.1068G>A、c.1222C>T、c.1292G>A、c.1358G>A和c.1359G>A。
- SpRY-ABE8e碱基编辑器联合guide RNA在所有靶位点成功诱导A>G转换。
- 小鼠体内变异恢复效率:c.1068G>A为62.8%±14.4%,c.1222C>T为35.9%±3.8%,c.1292G>A为70.6%±2.7%。
- LNP给药后血浆FIX活性增加。
临床怎么用
- 该平台支持针对F9无义变异的个性化碱基编辑治疗,需根据患者具体变异设计guide RNA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemophilia B is caused by loss-of-function variants in the F9 gene encoding factor IX (FIX). Although adeno-associated virus (AAV) vector-based gene therapy can restore FIX expression for over a decade, it does not restore the pathogenic variants and faces limitations related to immunogenicity and re-dosing. OBJECTIVES: To develop a variant-specific, nonviral base editing strategy using lipid nanoparticles (LNPs) for the precise personalized correction of pathogenic nonsense variations in F9. METHODS: Editing efficiency was evaluated in HEK293 cells harboring F9 variants treatable by A•T to G•C base editing. Functional and molecular restoration in vivo was assessed in hemophilia B model mice created with AAV8 vectors expressing F9 variants. LNPs harboring adenine base editor (Cas9 nickase conjugated with ABE8e) mRNA and the corresponding guide RNA were intravenously injected into the mice. RESULTS: We created HEK293 stably expressing 6 correctable nonsense variants: c.1067G>A, c.1068G>A, c.1222C>T, c.1292G>A, c.1358G>A, and c.1359G>A. Transfection of the cells with a base editor consisting of SpRY, an engineered SpCas9 with broader protospacer adjacent motif compatibility, and ABE8e, together with the guide RNA sequence, successfully induced A>G conversion at all target sites. The administration of LNPs harboring the base editor mRNA and guide RNA to the hemophilia B model restored the pathological variants (62.8% ± 14.4% for c.1068G>A, 35.9% ± 3.8% for c.1222C>T, and 70.6% ± 2.7% for c.1292G>A) and increased plasma FIX activity. CONCLUSION: This variant-specific, nonviral base editing platform represents a truly curative intervention for severe hemophilia B caused by single-nucleotide variants.
引用
- Hiya-Kawaguchi U, Kashiwakura Y, Baatartsogt N, et al. Nonviral delivery of a base editor enables personalized correction of hemophilia B nonsense variants in a mouse model. J Thromb Haemost. 2026. PMID: 42276271. doi:10.1016/j.jtha.2026.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。